日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sequential invitations to FOBT screening and colorectal cancer incidence

FOBT筛查的连续邀请与结直肠癌发病率

Wang, Xiaoqin; Ribbing Wilén, Hanna; Phillips, Rachael V; Wang, Zeyi; van der Laan, Mark J; Yin, Li; Blom, Johannes

Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases

尼达尼布治疗成人慢性纤维化间质性肺疾病的暴露-疗效荟萃模型

Hartmann, Sonja; Janssen, Julie; Ribbing, Jakob; Stowasser, Susanne; Korell, Julia

Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib

基于人群药代动力学和暴露-反应模型的贝叶斯方法,将基于FVC的疗效终点从成人患者外推至接受尼达尼布治疗的儿科患者

Hartmann, Sonja; Chan Kwong, Anna; Ribbing, Jakob; Gahlemann, Martina; Korell, Julia

Topical BET PROTACs for locally restricted protein degradation in the lung

局部应用BET PROTACs进行肺部局部限制性蛋白质降解

Hemmerling, Martin; Liu, Jianming; Piras, Antonio; Pehrson, Rikard; Hedström, Ulf; Cassani, Carlo; Ranieri, Beatrice; Kwapień, Karolina; Ribbing, Karin; Forss, Cecilia; Slettengren, Oliwia; Eisele, Frederik; Ding, Mei; Hansson, Pia; Novén, Anna; Nordberg, Markus; Park, Hyunsoo; Jarke, Annica; Rosenbaum, Lisa-Catherine; Malmberg, Jesper; Borde, Annika; Badolo, Lassina; Engsevi, Madeleine; Jirholt, Johan; Breccia, Perla; Schiesser, Stefan; Ripa, Lena; Czechtizky, Werngard

The effect on colorectal cancer incidence and staging with population-based FOBT-screening in Sweden

瑞典基于人群的粪便隐血试验筛查对结直肠癌发病率和分期的影响

Ribbing Wilén, Hanna; Jonsson, Håkan; Blom, Johannes

Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease

中重度活动性克罗恩病患者中依曲利珠单抗的群体药代动力学和暴露-反应关系

Moein, Anita; Ribbing, Jakob; Ibrahim, Moustafa M A; Zhang, Wenhui; Kassir, Nastya

Covariate modeling in pharmacometrics: General points for consideration

药物计量学中的协变量建模:需要考虑的一般要点

Sanghavi, Kinjal; Ribbing, Jakob; Rogers, James A; Ahmed, Mariam A; Karlsson, Mats O; Holford, Nick; Chasseloup, Estelle; Ahamadi, Malidi; Kowalski, Kenneth G; Cole, Susan; Kerwash, Essam; Wade, Janet R; Liu, Chao; Wang, Yaning; Trame, Mirjam N; Zhu, Hao; Wilkins, Justin J

Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test

在瑞典一项基于人群的筛查计划中,采用性别特异性粪便免疫化学试验临界值,进行两轮筛查后发现间隔期癌症

Ribbing Wilén, Hanna; Blom, Johannes

Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis

在患有中重度活动性溃疡性结肠炎的患者中,etrolizumab 的暴露-反应关系

Kassir, Nastya; Zhu, Rui; Moein, Anita; Langenhorst, Jurgen; Ribbing, Jakob; Zhang, Rong; Tang, Meina T; Oh, Young S; Zhang, Wenhui

Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis

对中重度活动性溃疡性结肠炎患者进行etrolizumab群体药代动力学分析

Moein, Anita; Lu, Tong; Jönsson, Siv; Ribbing, Jakob; Kassir, Nastya; Zhang, Wenhui; Sperinde, Gizette; Zhang, Rong; Tang, Meina; Oh, Young S; Bruno, Rene; Zhu, Rui